# Brian Atwood

> Brian Atwood is a Series B investor at Mission Bay Capital backing Biotechnology. See 12 investments, check sizes, portfolio and contact details. Updated Aug…

- Type: Angel Investor
- Fund: [Mission Bay Capital](https://shizune.co/investors/profile/mission-bay-capital-llc)
- Location: San Francisco, United States
- Total investments: 12
- Last investment: Oct 2013
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/brian-atwood-04014424

Brian Atwood is a Series B investor at Mission Bay Capital in San Francisco focused on Biotechnology and Health Care. Brian Atwood is the Managing Director at Versant Ventures. Prior to that, he was the Founder, President, and CEO of Glycomed. He attended the University of California Davis, the University of California, Irvine, and Harvard Business School.

## Contacts

5 contacts available for Brian Atwood: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/brian-atwood?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 50% |
| Health Care | 5 | 42% |
| Therapeutics | 3 | 25% |
| Medical | 2 | 17% |
| Genetics | 1 | 8% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 33% |
| Series A | 3 | 25% |
| Series C | 3 | 25% |
| Funding Round | 1 | 8% |
| Private Equity | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Immune Design | Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-basedproducts for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence | $49M | Series C | Oct 30, 2013 |  |
| Veracyte | Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoidrisky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. | $28M | Series C | Jun 28, 2013 |  |
| Five Prime Therapeutics | FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­callyrel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures. | $10M | Private Equity | Apr 20, 2012 |  |
| OpGen | Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with morerapid and actionable information about life threatening infections to improve patient outcomes. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications. | $17M | Series C | Mar 07, 2012 |  |
| Groove Biopharma | Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue ofnucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease. | $6M | Series B | Dec 12, 2011 |  |
| OpGen | Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with morerapid and actionable information about life threatening infections to improve patient outcomes. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications. | $17M | Series B | Sep 28, 2010 |  |
| Immune Design | Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-basedproducts for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence | $32M | Series B | Jul 26, 2010 |  |
| Veracyte | Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoidrisky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. | $28M | Series B | Jun 11, 2010 |  |
| Groove Biopharma | Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue ofnucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease. | $3.9M | Series A | Apr 26, 2010 |  |
| Immune Design | Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-basedproducts for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence | $18M | Series A | Jul 07, 2008 |  |

10 of 12 investments shown.

## Co-investors
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 3 deals together
- [CHL Medical Partners](https://shizune.co/investors/profile/chl-medical-partners) — VC Fund, 3 deals together
- [Highland Capital Partners](https://shizune.co/investors/profile/highland-capital-partners) — VC Fund, 3 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 3 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 3 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together

## About Mission Bay Capital

VC Fund · San Francisco, United States

Mission Bay Capital is a venture capital firm for early-stage investments.

5 contacts available at Mission Bay Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Ralph E. Christofferson | Partner | — |
| Brian Atwood | Managing Partner | — |
| Brook Byers | Partner | https://shizune.co/investors/profile/brook-byers |
| David DesJardins | Investor | — |
| Doug Cameron | Partner | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Brian Atwood invest in?

Brian Atwood invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Brian Atwood?

Public channels for Brian Atwood include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Brian Atwood last invest?

The most recent investment recorded for Brian Atwood closed in Oct 2013. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co